Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda names new CEO of Takeda Pharmaceuticals Europe
Dr Brunn has a doctorate in chemistry and, since 2001, has been president of Takeda Pharma, a wholly owned subsidiary of Takeda in Germany. He previously worked at
Dr Brunn has a doctorate in chemistry and, since 2001, has been president of Takeda Pharma, a wholly owned subsidiary of Takeda in Germany. He previously worked at
Thrombin alfa is a recombinant form of human thrombin that is structurally and functionally similar to the natural enzyme which is an important factor in the blood clotting
The data showed that DU-176b reduced the incidence of venous thromboembolism compared with dalteparin among patients undergoing elective unilateral hip replacement surgery. There was a statistically significant dose
The drug is a generic version of Abbott Laboratories’ Mavik tablets and is indicated for the treatment of hypertension.
Allegheny General Hospital in Pittsburgh, Pennsylvania, Erasmus Medical Center in Rotterdam, Netherlands, and Froedtert Memorial Lutheran Hospital in Milwaukee, Wisconsin, have all begun producing treatment plans with the
The Change Champion network is said to be a communications channel developed for interaction between the Dubai Health Authority (DHA) and the public and private healthcare sectors. Members
Bayer has filed with the European Medicines Agency for authorization to market Recothrom as a topical aid to control surgical bleeding. Recothrom received FDA approval in January 2008.
Under the terms of the drug discovery contract, Evotec will receive a milestone payment from Boehringer Ingelheim which was granted for the selection of an advanced compound for
Biosensors said that Leaders is the first head-to-head randomized study between the two drug-eluting stent systems (DES) in a ‘real world, all comers’ population using clinical results as
The project, named Debio 0826, could lead to the development of potential therapeutic compounds and to the identification of new targets to fight cancer stem cells. Following the